Research and experimental development on natural sciences and engineering
BIOPHARMIA AS
Revenue 2025
NOK 0
Operating profit
NOK −80,000
Equity
NOK 8.1m
Incorporated
2009
Share capital
NOK 112,000
Key figures · 2025
Current ratio
0.00
Equity ratio
76.4%
Key figures over time · 2025
| Key figures | 2025 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Return on assets (%%) | -0.8% | |
| Likviditet | ||
| Current ratio | 0.00 | |
| Working capital | −14 | |
| Soliditet | ||
| Equity ratio (%%) | 76.4% | |
| Debt-to-equity ratio | 0.31 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.